Twelve further issuer cases examine original financial statements, financing, business changes and the evidence needed for a valuation. All twelve remain NotRated: no new current rating or price target is supported by this batch. Conditional models explain the decision; they do not issue targets.
Research compiled 2026-10-24T06:43:14.192221+00:00. Original financial periods and publication dates remain fixed. A source check is not a new company result or a renewed investment opinion.
12Further issuer case reviews
0New issued ratings or targets
2Specific legacy financial summaries held
312Tracked listing rows · not unique issuers
Current evidence and historical evidence are separate. IDT and Blue Line use clearly dated historical originals where the newer full accounts could not be verified. InMed and Elixinol expose concrete scale, period or business-scope errors in older summaries; those summaries are held in Analyst and Financials. Other valid dated records are preserved. This batch does not add twelve ratings or certify all directory companies.
HYFM · NASDAQ (latest issuer identification; current compliance resolution unverified)
Hydrofarm Holdings Group, Inc.
NotRated · target withheld
No current recommendation, target or upside is issued here.
Evidence confidence: High for directly captured filed figures; medium for issuer event descriptions and bounded index freshness. Underwriting/current-target readiness is separately held. Underwriting status: Preliminary underwrite; a supported current equity valuation remains incomplete.
Business and cannabis exposure: Controlled-environment agriculture equipment, nutrients and grow media; upstream cannabis/horticultural exposure, not direct cannabis sales.
Security: Common stock, USD 0.0001 par. June common shares are a historical filed count; a fresh corporate-action/current listing check is still required.
Saved quote observation: USD 0.795 dated 2026-10-23T20:00:00.000Z. This retained observation is not independently certified as a current exchange close, and no target return is computed from it.
CIN’s investment read
The relevant unit of analysis is the continuing business after Aurora and any lender transaction; pre-disposal sales and assets cannot support an unchanged post-disposal multiple.
Cost reductions need to restore recurring gross cash profit before a common-equity valuation becomes reliable.
Separate unrestricted liquidity from pledged cash and deferred interest. The forbearance disclosed in August is not assumed extended into October.
Why the rating and target are withheld
A lender-default/restructuring equity option: post-August forbearance and post-September Nasdaq status, debt after disposal/fees and fully diluted post-financing common equity are not established in accessible originals.
Original reported figures and dated disclosures
Units, reporting periods and publication dates stay separate. Company statements and CIN assumptions are identified by line; historical facts are not current cash or current ownership.
Conditional capital, funding and valuation work · not price targets
Sensitivity, not an issued opinion. Forecasts, cost assumptions, multiples, discount rates, financing allowances and trial outcomes below are CIN analytical inputs. No probability of clinical success, funded share value or current target is implied by a cash-runway or break-even calculation.
Illustrative distressed EV-to-common waterfall, after operating rent; not a liquidation appraisal, enterprise appraisal or price target.
Capital and claim bridge
Term principal usdm
114.4
Finance lease pv usdm
7.603
Other debt usdm
0.1
Unrestricted cash usdm
6.154
Net financial claim threshold usdm
115.949
Operating lease pv usdm
36.091
Lease convention
EV is assumed after operating cash rent; operating-leasePV is not subtracted again. Finance leases remain financial claims. No favorable debt forgiveness is assumed.
App sale
July 31 total 16 m consideration includes 5 m promissory note; maximum 11 m headline cash before interest/fees/adjustments is not a demonstrated principal reduction. The disposed operating asset is absent from continuing-EV assumptions.
Shares
June 4.814612 m is historical common stock, not a post-restructuring fully diluted denominator. Awards/conversion/restructured ownership are unknown.
Nci preferred
No separate balance is supplied in the accessible earnings balance sheet; no clean-capital-stack claim is made.
Bear · conditional only
Assumed continuing ev usdm
20
June debt plus finance leases less unrestricted cash usdm
115.949
Conditional common residual usdm
0
Conditional usd per june common share
0
Explanation
CIN assumed after-operating-rent enterprise valueUSD20 m less illustrative June net financial claimsUSD115.949 m leavesUSD0.000 m before unknown fees/restructuring/new equity. Zero is a scenario residual, not a zero-dollar target.
Base · conditional only
Assumed continuing ev usdm
45
June debt plus finance leases less unrestricted cash usdm
115.949
Conditional common residual usdm
0
Conditional usd per june common share
0
Explanation
CIN assumed after-operating-rent enterprise valueUSD45 m less illustrative June net financial claimsUSD115.949 m leavesUSD0.000 m before unknown fees/restructuring/new equity. Zero is a scenario residual, not a zero-dollar target.
Bull · conditional only
Assumed continuing ev usdm
80
June debt plus finance leases less unrestricted cash usdm
115.949
Conditional common residual usdm
0
Conditional usd per june common share
0
Explanation
CIN assumed after-operating-rent enterprise valueUSD80 m less illustrative June net financial claimsUSD115.949 m leavesUSD0.000 m before unknown fees/restructuring/new equity. Zero is a scenario residual, not a zero-dollar target.
CIN assumptions
20/45/80 m enterprise values are CIN stress assumptions, not observable deal prices or comparable-company medians.
The waterfall freezes June financial claims solely to reveal the equity hurdle; it is not an October debt statement.
No proceeds from a future rescue issuance, debt haircut or asset sale are credited to existing shareholders.
What the diagnostic cannot establish
Current lender protection/default remedy and Nasdaq compliance status unverified after disclosed deadlines.
Full current dilution/creditor waterfall unavailable.
Issuer SEC index returned 403; not retried. The Q2 Form 10-Q link could not be read by the browser tool; earnings tables were used without inventing missing footnotes.
Risks and downside mechanism
Creditors may accelerate, enforce collateral, require asset sales or equitize claims; existing shares can be impaired independently of brand survival.
Further sales contraction, supplier/credit pressure and working-capital needs could exhaust a small unrestricted cash balance.
Nasdaq April notice and possibleSeptember 28 extension require a later resolution; the storedNasdaq quote is not proof of current listing compliance.
Cash-flow improvement may reflect reduced inventory rather than sustainable volume and margin.
Next evidence and thesis tests
A definitive lender/forbearance or recapitalization agreement with an exact common-equity allocation.
Original Q3 accounts showing continuing operations, post-Aurora debt and unrestricted cash.
An original exchange/issuer filing confirming current listing/security basis.
No funded near-term liquidity solution.
A transaction allocates no economic residual to existing common shares.
Cost savings fail to offset recurring revenue declines.
Original sources and access limits
Hydrofarm Q2 2026 original results and financial tables · Published 2026-08-14 · Covered period Q2/H1 ended 2026-06-30 Results; liquidity/strategic alternatives; balance sheet; FCF reconciliation original public source read
Hydrofarm original April 7 Form 8-K listing notice · Published 2026-04-07 · Covered period Event 2026-04-01 Nasdaq market-value/equity compliance notice; possible extension only throughSeptember 28 original public source read
Hydrofarm original April 14 Form 8-K forbearance · Published 2026-04-14 · Covered period Agreement 2026-04-08 Item 1.01; default notice February 11; minimum liquidity covenant original public source read
Hydrofarm investor news index · Published not verified · Covered period Bounded index observation Latest visible resultsAugust 14 and asset-sale newsAugust 3; index is not proof of no later filings original public source read
Original dates are retained. Bounded source checks are not a complete corporate-actions feed. Author holdings, issuer compensation, relationships and trading conflicts have not been supplied; no absence-of-conflict claim is made.
No current recommendation, target or upside is issued here.
Evidence confidence: High for directly captured filed figures; medium for issuer event descriptions and bounded index freshness. Underwriting/current-target readiness is separately held. Underwriting status: Preliminary underwrite; a supported current equity valuation remains incomplete.
Business and cannabis exposure: Hemp-derived CBD and botanical wellness products; not marijuana cultivation/retail.
Security: One issued class of common shares; no preferred outstanding atJune 30. OTC CWBHF/TSX CWEB issuer identification is source verified, while the saved quote has only genericOTC metadata.
Saved quote observation: USD 0.2602 dated 2026-10-23T17:15:00.000Z. This retained observation is not independently certified as a current exchange close, and no target return is computed from it.
CIN’s investment read
Judge recurring operating cash economics after rent, rather than fair-value gains or debt-extinguishment accounting.
The BAT conversion removed financial debt but enlarged the common denominator and established a substantial strategic shareholder.
Cash break-even requires better mix and a materially lower cost base; a channel pivot or policy announcement does not prove demand.
Why the rating and target are withheld
The core-only DCF needs an explicit funded transition from June 2026 to the October 2027 valuation date: operating cash flow, working capital, capex, costs and diluted units. The assumed target-date cash and 2028 margin recovery are not yet bridged. A generic OTC label versus the issuer’s OTCQX tier is not itself a demonstrated different security, and no speculative reimbursement revenue is needed for this core-only model.
Original reported figures and dated disclosures
Units, reporting periods and publication dates stay separate. Company statements and CIN assumptions are identified by line; historical facts are not current cash or current ownership.
Conditional capital, funding and valuation work · not price targets
Sensitivity, not an issued opinion. Forecasts, cost assumptions, multiples, discount rates, financing allowances and trial outcomes below are CIN analytical inputs. No probability of clinical success, funded share value or current target is implied by a cash-runway or break-even calculation.
Conditional three-year after-operating-rent FCFF DCF at an illustrative October 2027 valuation date; no CMMI or DeFloria operating revenue assumed.
Capital and claim bridge
June common m
270.549931
Full june options and rsus m
7.703015
Full june gross dilution m
278.252946
Scenario fully diluted units m
285
280
285
Unit convention
Include all June options and RSUs without exercise proceeds, then an explicit allowance for future grants/funding. Scenario units are not a proven October register.
June cash usdm
13.988
Target cash usdm
4
8
11
Cash convention
Cash at the target date is assumed after operating, working-capital and capex uses. It is not current cash or a second June cash addback; no financing proceeds are credited.
Financial debenture usdm
0
Lease convention
Forecast EBITDA and FCFF are after continuing cash rent. Do not deduct the 13.055 m operating-lease PV a second time. Cash rent remains in ongoing costs.
Unconsolidated investment
The 8.3 m June carrying value is not cash. A separate 0/0/2 m sensitivity is used without royalties or cash flows from that investment in the core forecast.
Nci preferred
No preferred shares or separate NCI line were reported in the reviewed balance sheet. The investment is unconsolidated and cannot be treated as 100%-owned cash.
Bear · conditional only
Forecast calendar years
2,028
2,029
2,030
Cin revenue usdm
32
33
34
After rent ebitda margin
-0.05
0
0.03
After rent ebitda usdm
-1.6
0
1.02
Depreciation usdm each year
1
Capex usdm each year
0.8
Working capital investment usdm each year
0.2
Cash tax rate positive ebit
0.25
Fcff usdm
-2.6
-1
0.015
Discount rate
0.22
Terminal growth
0
Terminal value usdm
0.068182
Target date operating ev usdm
-2.757201
Assumed cash at target usdm
4
Conditional unconsolidated investment value usdm
0
Conditional equity usdm
1.242799
Assumed diluted common m
285
Conditional usd per common share
0.004361
Explanation
CIN forecasts 2028–30 core revenue of[32, 33, 34]m, after-rent EBITDA margins of[-0.05, 0, 0.03], and taxes only on positive EBIT. At 22% discount rate/0% terminal growth, operating EV is USD-2.757 m. Add assumed target cash USD 4 m and separate investment value USD 0 m, divide by 285 m assumed units: USD 0.0044, conditional only.
Base · conditional only
Forecast calendar years
2,028
2,029
2,030
Cin revenue usdm
42
46
50
After rent ebitda margin
0.05
0.08
0.1
After rent ebitda usdm
2.1
3.68
5
Depreciation usdm each year
1
Capex usdm each year
0.8
Working capital investment usdm each year
0.2
Cash tax rate positive ebit
0.25
Fcff usdm
0.825
2.01
3
Discount rate
0.18
Terminal growth
0.01
Terminal value usdm
17.823529
Target date operating ev usdm
14.816546
Assumed cash at target usdm
8
Conditional unconsolidated investment value usdm
0
Conditional equity usdm
22.816546
Assumed diluted common m
280
Conditional usd per common share
0.081488
Explanation
CIN forecasts 2028–30 core revenue of[42, 46, 50]m, after-rent EBITDA margins of[0.05, 0.08, 0.1], and taxes only on positive EBIT. At 18% discount rate/1% terminal growth, operating EV is USD 14.817 m. Add assumed target cash USD 8 m and separate investment value USD 0 m, divide by 280 m assumed units: USD 0.0815, conditional only.
Bull · conditional only
Forecast calendar years
2,028
2,029
2,030
Cin revenue usdm
52
60
68
After rent ebitda margin
0.1
0.13
0.15
After rent ebitda usdm
5.2
7.8
10.2
Depreciation usdm each year
1
Capex usdm each year
0.8
Working capital investment usdm each year
0.2
Cash tax rate positive ebit
0.25
Fcff usdm
3.15
5.1
6.9
Discount rate
0.16
Terminal growth
0.02
Terminal value usdm
50.271429
Target date operating ev usdm
43.132962
Assumed cash at target usdm
11
Conditional unconsolidated investment value usdm
2
Conditional equity usdm
56.132962
Assumed diluted common m
285
Conditional usd per common share
0.196958
Explanation
CIN forecasts 2028–30 core revenue of[52, 60, 68]m, after-rent EBITDA margins of[0.1, 0.13, 0.15], and taxes only on positive EBIT. At 16% discount rate/2% terminal growth, operating EV is USD 43.133 m. Add assumed target cash USD 11 m and separate investment value USD 2 m, divide by 285 m assumed units: USD 0.1970, conditional only.
CIN assumptions
All 2028–30 revenue and margin forecasts, discount rates and terminal growth rates are CIN judgment, not issuer guidance or consensus.
Base 5–10% EBITDA margins require a substantial cost reduction versus current performance. This is an unproven turnaround, not a conservative extrapolation.
Positive EBIT is taxed at 25% with no NOL benefit; negative EBIT receives no cash-tax credit.
No further BAT debenture repayment is deducted: the instrument was converted. No hypothetical new investment is credited as cash.
What the diagnostic cannot establish
The issuer identifies the same common class as TSX CWEB and OTCQX CWBHF. A generic OTC label alone does not prove a wrong listing or share adjustment.
June cash and historical burn do not establish imminent funding failure. A conservative source-anchored interim cash, capex, working-capital, cost and share bridge is needed before selecting a current target.
The core forecast assigns no operating revenue to speculative reimbursement or clinical commercialization. Those possibilities do not supply the missing transition bridge.
Risks and downside mechanism
Operating losses can consume recapitalization cash before the margin plan works.
Hemp-product rules, channel resets and compliance can impair sales; policy optimism is not authorization or reimbursement.
BAT held 40.6% at closing, which affects control and float. Current holdings and trading conflicts remain unverified.
Related-party or zero-margin supply can increase revenue without comparable cash returns.
Next evidence and thesis tests
Original Q3 results showing costs, postconversion common shares and channel-specific sales.
A funded path to cash break-even, reconciled to cash rather than EBITDA adjustments.
Actual reimbursed orders and qualified healthcare distribution, supported by original regulatory evidence if they occur.
Another material increase in cash losses without funding.
Gross-margin improvement fails to cover cash operating costs.
New financing materially exceeds the modeled dilution allowance.
Charlotte's Web original Q2 2026 results · Published 2026-08-13 · Covered period Q2/H1 ended 2026-06-30 Recapitalization completion; channel mix; cash-flow discussion original public source read
Original BAT conversion and equity proposal · Published 2026-03-30 · Covered period Proposal subsequently completedMay 28 Distinguish proposed March terms from completed Q2 share counts original public source read
Charlotte's Web issuer news index · Published not verified · Covered period Bounded observation 2026-10-24 Latest visibleSeptember 2 policy response; not a full legal/corporate-action clearance original public source read
Original dates are retained. Bounded source checks are not a complete corporate-actions feed. Author holdings, issuer compensation, relationships and trading conflicts have not been supplied; no absence-of-conflict claim is made.
No current recommendation, target or upside is issued here.
Evidence confidence: High for directly captured filed figures; medium for issuer event descriptions and bounded index freshness. Underwriting/current-target readiness is separately held. Underwriting status: Preliminary underwrite; a supported current equity valuation remains incomplete.
Business and cannabis exposure: Retail-led regulated THC cannabis in Ohio and Arizona, with cultivation/manufacturing where economical.
Security: Subordinate voting shares;618,907 unlistedmultiple-votingshares convert 100:1 into 61,890,700 subordinate equivalents. Do not value only the 185.816341 m listedsubordinates.
Saved quote observation: USD 0.178 dated 2026-10-23T19:59:00.000Z. This retained observation is not independently certified as a current exchange close, and no target return is computed from it.
CIN’s investment read
Value the entire ordinary-equivalent equity, including multiple-voting shares. Listed shares alone are not the economic denominator.
A property purchase financed with amortizing debt can improve asset control, but is not a free cash raise.
Ohio growth matters when incremental cash covers interest, taxes, maintenance capex and amortization without new dilution.
Why the rating and target are withheld
A current common target requires reconciliation of post-August face debt, Ohio note-extension conditions, property-sale/debt use and tax/after-rent cash economics. Conditional capital-stack sensitivities are not issued targets.
Original reported figures and dated disclosures
Units, reporting periods and publication dates stay separate. Company statements and CIN assumptions are identified by line; historical facts are not current cash or current ownership.
Conditional capital, funding and valuation work · not price targets
Sensitivity, not an issued opinion. Forecasts, cost assumptions, multiples, discount rates, financing allowances and trial outcomes below are CIN analytical inputs. No probability of clinical success, funded share value or current target is implied by a cash-runway or break-even calculation.
Conditional after-operating-rent adjustedEBITDA EV sensitivity, with explicit debt/tax/noncore-asset bridge; not an issued target or peer-median valuation.
Capital and claim bridge
June notes carrying value usdm
29.792
Old wpcu carrying value usdm
10.115
August refinanced old wpcu face usdm approx
10.3
August new wpcu face usdm
17
Net new principal usdm approx
6.7
Property purchase usdm
6
New wpcu interest rate
0.0864
Illustrative replacement debt proxy usdm
36.677
Debt proxy limitation
USD 36.677 m replaces the old WPCU carrying balance with the new 17 m face principal, but other balances remain carrying amounts. It is not a complete October face-debt statement;36/37/38 m scenario debt is assumed.
June app note carrying usdm
5.633
September terms
The issuer agreed to a 2.4 m cash payment in early January 2027 and 3.2 m replacement notes amortizing over 24 months, at 10% fromJanuary 2027, with about 147 k monthly payments fromFebruary 15. Conditions, including the next quarterly payment, remain unverified.
June cash usdm
4.535
June current and uncertain tax usdm
13.023
June deferred tax liability usdm
9.521
Lease convention
Deduct annual cash rent from the EBITDA metric before applying the multiple; do not subtract lease PV again. The 1.2–1.4 m rent estimate assumes continuity; ownership of the Jackson property may change actual rent.
Noncore sale convention
Add assumed net Eloy proceeds once while retaining gross debt. Do not also reduce debt by those proceeds. Completion of a sale is not asserted.
Fully diluted
247.707041 m ordinary equivalents plus 5.764284 m options, a 0.100 m conservative RSU allowance and 0.280 m advisory warrants. No exercise proceeds. The IR100 k RSU label and the financial statement 66,667 units have different clocks; use the higher allowance without claiming a correction.
Nci preferred
No separate NCI or preferred-equity line appears in the reviewed consolidated June statement. This is not a claim that no later claims can arise.
Bear · conditional only
Forward cin adjusted ebitda before cash rent usdm
10
Annual cash rent usdm
1.4
After rent metric usdm
8.6
Selected ev multiple
4
Conditional operating ev usdm
34.4
Assumed face financial debt usdm
38
Assumed free cash usdm
2
Net noncore eloy value usdm
4
Cash tax liability reserve usdm
22.544
Conditional equity usdm
0
Conservative units m
253.851325
Conditional usd per subordinate equivalent
0
Explanation
CIN pre-rent adjusted EBITDA USD 10 m less cash rent USD 1.4 m, at 4 x, gives EV USD 34.400 m. Less assumed debt USD 38 m, plus cash USD 2 m and noncore proceeds USD 4 m, less tax reserve USD 22.544 m, over 253.851325 m units gives USD 0.0000. Conditional sensitivity, not a target.
Base · conditional only
Forward cin adjusted ebitda before cash rent usdm
14
Annual cash rent usdm
1.3
After rent metric usdm
12.7
Selected ev multiple
5
Conditional operating ev usdm
63.5
Assumed face financial debt usdm
37
Assumed free cash usdm
4
Net noncore eloy value usdm
6
Cash tax liability reserve usdm
13.023
Conditional equity usdm
23.477
Conservative units m
253.851325
Conditional usd per subordinate equivalent
0.092483
Explanation
CIN pre-rent adjusted EBITDA USD 14 m less cash rent USD 1.3 m, at 5 x, gives EV USD 63.500 m. Less assumed debt USD 37 m, plus cash USD 4 m and noncore proceeds USD 6 m, less tax reserve USD 13.023 m, over 253.851325 m units gives USD 0.0925. Conditional sensitivity, not a target.
Bull · conditional only
Forward cin adjusted ebitda before cash rent usdm
18
Annual cash rent usdm
1.2
After rent metric usdm
16.8
Selected ev multiple
6
Conditional operating ev usdm
100.8
Assumed face financial debt usdm
36
Assumed free cash usdm
5
Net noncore eloy value usdm
7.5
Cash tax liability reserve usdm
13.023
Conditional equity usdm
64.277
Conservative units m
253.851325
Conditional usd per subordinate equivalent
0.253207
Explanation
CIN pre-rent adjusted EBITDA USD 18 m less cash rent USD 1.2 m, at 6 x, gives EV USD 100.800 m. Less assumed debt USD 36 m, plus cash USD 5 m and noncore proceeds USD 7.5 m, less tax reserve USD 13.023 m, over 253.851325 m units gives USD 0.2532. Conditional sensitivity, not a target.
CIN assumptions
Forward EBITDA, rent, multiples, debt, cash, sale proceeds and reserves are CIN scenario judgments, not issuer guidance or peer medians.
The base tax reserve includes current tax and the uncertain tax position. The bear case also reserves the entire deferred-tax liability; no case assumes uncertain taxes are forgiven.
The selected multiples reflect risk but do not establish normalized after-financing FCF. No benefit from a 280 E repeal is assumed.
Include all option units without proceeds, including out-of-money awards, as a conservative dilution sensitivity. CAD exercise prices are not silently treated as USD.
What the diagnostic cannot establish
A current face-debt versus fair-value reconciliation and postfinancing cash statement are still needed.
The conditional October 1 seller-note extension is not assumed completed merely because its expected date passed.
Normalized cash taxes and maintenance versus growth capex remain incomplete. Book NAV includes licenses and property; it is not liquid common equity.
Risks and downside mechanism
Tax obligations and principal payments can absorb operating cash despite positive EBITDA.
Ohio product issues, pricing pressure and competition can reduce cash generation after restocking.
Real-estate collateral, cross-defaults and required sale proceeds limit flexibility.
Dual-class control and limited float amplify governance and trading-liquidity risk.
Next evidence and thesis tests
Original Q3 statements confirming WPCU/APP balances, extension conditions, cash and tax payments.
A closed Eloy disposal and actual required debt repayment.
Post-hold recovery in like-for-like retail and wholesale cash sales.
Debt and tax cash uses consistently exceed retail cash generation.
A maturity condition or product-compliance problem recurs.
New capital or creditor priority materially reduces common residual value.
Original sources and access limits
Vext original June 2026 interim financial statements · Published 2026-08-20 · Covered period Q2/H1 ended 2026-06-30 PDFpp 4-7 statements;18-20 debt;20-23 capital;25 taxes;26-27 subsequentevents. Unaudited and noauditorreview. original public source read
Vext original Q2 2026 results · Published 2026-08-20 · Covered period Q2 ended 2026-06-30 Reported and adjustedEBITDA bridge; operatingcash; Arizona winddown original public source read
Vext original Jackson product-hold update · Published 2026-10-15 · Covered period EventOctober 14 IssuerreportsDCCreleasedproducthold; wholesale/retailrestocking; notindependentlyexaminedDCCorder original public source read
Vext original share-capitalization table · Published not verified · Covered period Sharesasat 2026-08-19/optionssectionasatApril 29 Equivalentmultiple-votingshares; differingtableclocks retained original public source read
CSE Vext issuer listing · Published not verified · Covered period Bounded observation 2026-10-24 ActiveT2;185.816341 mlistedshares;reservedissuance 68.044984 m isnotanadditionalcommondenominator original public source read
Original dates are retained. Bounded source checks are not a complete corporate-actions feed. Author holdings, issuer compensation, relationships and trading conflicts have not been supplied; no absence-of-conflict claim is made.
No current recommendation, target or upside is issued here.
Evidence confidence: High for directly captured filed figures; medium for issuer event descriptions and bounded index freshness. Underwriting/current-target readiness is separately held. Underwriting status: Preliminary underwrite; a supported current equity valuation remains incomplete.
Business and cannabis exposure: Consumer hemp-extract wellness, other nutraceuticals and plant-basedfoods; no assumedmedicalor drugcommercializationvalue.
Security: Delawarecommonstock,USD 0.0001 par; August 11 common 225,829,128. GenericOTC savedquotemetadataisnot independentOTCQB/securityadjustmentverification.
Saved quote observation: USD 0.0105 dated 2026-10-23T19:47:00.000Z. This retained observation is not independently certified as a current exchange close, and no target return is computed from it.
CIN’s investment read
Establish recurring core-brand cash profit before adding clinical-development or new-platform option value.
The convertible fair-value liability is not a contractual payoff or a dilution ceiling.
A fixed conversion price does not bound the common denominator when sale-proceeds shortfalls create additional notes.
Why the rating and target are withheld
A recursive note-sale shortfall/true-up mechanism and current after-financing fully diluted denominator are unresolved; a low quoted price is not enough to establish per-share value or a supported target.
Original reported figures and dated disclosures
Units, reporting periods and publication dates stay separate. Company statements and CIN assumptions are identified by line; historical facts are not current cash or current ownership.
Conditional capital, funding and valuation work · not price targets
Sensitivity, not an issued opinion. Forecasts, cost assumptions, multiples, discount rates, financing allowances and trial outcomes below are CIN analytical inputs. No probability of clinical success, funded share value or current target is implied by a cash-runway or break-even calculation.
Conditional after-rent normalizedoperating-FCF enterprise sensitivity, followed by explicit assumed financing/dilution reserves; no issued target.
Inputs and their limits
Normalized fcf definition
Conditional unlevered FCF after operating cash rent, maintenance capex, working-capital needs and cash taxes, before financial interest/settlement/funding. Assumed values are not issuer guidance or a completed forecast.
Capital and claim bridge
June common m
213.122
August 11 common m
225.829128
Postquarter reported conversion shares
12,706,600
Postquarter thirdnote usd
71,811
Postquarter principal converted usd
381,198
March amended principal usd
2,256,000
H1 principal converted usd
1,257,684
Q2 thirdnotes principal usd
366,090
Mechanical june face before unreported changes usd
1,364,406
Mechanical august face before unreported changes usd
1,055,019
Face bridge limitation
Arithmetic from disclosed principal changes only, not an October payoff statement. Unreported interest, payments or additional true-ups are not assumed complete.
Conversion terms
Amended Notes convert at 0.03 per share. Third Notes use the lesser of 0.03 or the close before their original issuance. Net sale-proceeds shortfalls over 94 k can create new notes. A conversion is not new cash received by the issuer.
June convertible fv usdm
1.017
Lease convention
Normalized FCF is after cash rent; do not deduct the 0.218 m lease PV again.
Awards
53.812 m June options plus 6.75 m contingent Mona options. Current terms and vesting need reconciliation;300–450 m scenario units are not a capital register.
Nci preferred
No separate NCI and no preferred shares outstanding were reported in June. Subsidiaries remain consolidated; later claims are not assumed absent.
Bear · conditional only
Cin normalized after rent before financing fcf usdm
0.15
Selected ev fcf multiple
6
Conditional operating ev usdm
0.9
Assumed cash usdm
0.2
Assumed cash settlement reserve usdm
1.5
New funding need usdm
1.5
Conditional equity usdm
0
Assumed post financing diluted common m
450
Conditional usd per share
0
Explanation
CIN normalized after-rent FCF USD 0.15 m at 6 x gives EV USD 0.8999999999999999 m. Add cash USD 0.2 m, deduct settlement reserve USD 1.5 m and new funding need USD 1.5 m, over 450 m assumed units: USD 0.00000. Debt and dilution are joint conservative stresses, not an actual conversion forecast or target.
Base · conditional only
Cin normalized after rent before financing fcf usdm
0.5
Selected ev fcf multiple
8
Conditional operating ev usdm
4
Assumed cash usdm
0.2
Assumed cash settlement reserve usdm
1.3
New funding need usdm
1
Conditional equity usdm
1.9
Assumed post financing diluted common m
350
Conditional usd per share
0.005429
Explanation
CIN normalized after-rent FCF USD 0.5 m at 8 x gives EV USD 4.0 m. Add cash USD 0.2 m, deduct settlement reserve USD 1.3 m and new funding need USD 1.0 m, over 350 m assumed units: USD 0.00543. Debt and dilution are joint conservative stresses, not an actual conversion forecast or target.
Bull · conditional only
Cin normalized after rent before financing fcf usdm
1
Selected ev fcf multiple
10
Conditional operating ev usdm
10
Assumed cash usdm
0.3
Assumed cash settlement reserve usdm
1.1
New funding need usdm
0.5
Conditional equity usdm
8.7
Assumed post financing diluted common m
300
Conditional usd per share
0.029
Explanation
CIN normalized after-rent FCF USD 1 m at 10 x gives EV USD 10 m. Add cash USD 0.3 m, deduct settlement reserve USD 1.1 m and new funding need USD 0.5 m, over 300 m assumed units: USD 0.02900. Debt and dilution are joint conservative stresses, not an actual conversion forecast or target.
CIN assumptions
Normalized FCF, multiples, settlement reserves, funding needs and share denominators are CIN sensitivities, not issuer plans or peer medians.
Do not credit new cash for note conversions. An actual cash raise requires its own price, fees and dilution bridge.
Positive CFO does not certify runway. Inventory and financing liabilities are not assumed immediately cash settled.
What the diagnostic cannot establish
Current recursive true-up exposure and fully diluted capital cannot be bounded from the available record.
Generic OTC quote metadata does not independently confirm the current OTCQB security basis.
No pharmaceutical success, legal market clearance or revenue from a product launch is manufactured.
Risks and downside mechanism
Dilution can continue after conversion when realized sale proceeds fail the true-up test.
A small cash balance and working-capital obligations constrain optional investment.
CBD/hemp rules and channel pressure can offset cost reductions.
Contingent awards and litigation or development obligations complicate the common claim.
Next evidence and thesis tests
Original Q3 capitalization and a current reconciliation of every amended note, Third Note and true-up.
Recurring cash generation apart from inventory and payable movements.
Measured margin and cash contribution from broader wellness products.
New Third Notes increase faster than existing claims are reduced.
Liquidity requires deeply discounted equity without operating improvement.
Core gross profit declines below the cash cost floor.
Original sources and access limits
CV Sciences original June 2026 Form 10-Q · Published 2026-08-13 · Covered period Q2/H1 ended 2026-06-30 Cover;statementpp 1-5;Notes 4 leases/6 convertibles/7 awards;liquidity original public source read
CV Sciences original Q2 2026 results · Published 2026-08-13 · Covered period Q2/H1 ended 2026-06-30 Sales/margins/cash and productdiversificationdiscussion original public source read
CV Sciences issuer news index · Published not verified · Covered period Bounded observation 2026-10-24 LatestvisibleSeptember 8 policyresponse;August 11 PlusHLTHlaunch. Notindependentlegalclearance. original public source read
CV Sciences issuer SEC filing index · Published not verified · Covered period Bounded observation 2026-10-24 Latestvisiblequarterly/currentreportAugust 13;notacertifiedno-latereventfeed. original public source read
Original dates are retained. Bounded source checks are not a complete corporate-actions feed. Author holdings, issuer compensation, relationships and trading conflicts have not been supplied; no absence-of-conflict claim is made.
No current recommendation, target or upside is issued here.
Evidence confidence: high for captured reviewed H 1/September originals; medium for successfully read official Q 3 text; full later-document capture rate-limited 429 Underwriting status: Not Rated; substantive operating case, incomplete current equity capital bridge
Business and cannabis exposure: Australian hemp foods/nutrition/wellness; US CBD asset business sold Sep 4. Retains Elixinol brand outsideUS.
Security: Ordinary shares; ASX code EXL
Capital and unit basis: Not reconciled:June 413,987,731 ordinary shares; September presentation cites rounded 438.2 m; later Vitable tranches and convertible terms not fully captured.
Saved quote observation: AUD 0.007 dated 2026-10-22. This retained observation is not independently certified as a current exchange close, and no target return is computed from it.
CIN’s investment read
The investable question is whether improved hemp/nutrition gross profit can become cash available to ordinary holders after expensive funding and proposed acquisition dilution. The original continuing-operation comparison improves, whereas the retained card mixes period and scope. Neither an adjusted cashflow label nor low revenue multiple establishes cheap equity.
Why the rating and target are withheld
The post-US-sale operating case is credible enough to research, but current fully diluted conversion/acquisition/financing claims are not reconciled and adjusted cashflow is not distributable cash.
Original reported figures and dated disclosures
Units, reporting periods and publication dates stay separate. Company statements and CIN assumptions are identified by line; historical facts are not current cash or current ownership.
Conditional capital, funding and valuation work · not price targets
Sensitivity, not an issued opinion. Forecasts, cost assumptions, multiples, discount rates, financing allowances and trial outcomes below are CIN analytical inputs. No probability of clinical success, funded share value or current target is implied by a cash-runway or break-even calculation.
Conditional enterprise-value sensitivity on hypothetical after-rent EBITDA; no share price target
Inputs and their limits
Basis
Standalone Australian operations; excludes Vitable profits and any drug/CBD optionality
Horizon
next 12 months sensitivity, not issuer guidance
Interest and claims
No equity bridge completed; lease cash costs included in operating-cost assumptions, so no second lease capitalization is applied.
Capital and claim bridge
June 30 borrowings carrying aud
3,753,000
June 30 leases aud
278,000
June 30 deferred consideration aud
267,000
June 30 contingent consideration aud
1,521,000
June 30 cash aud
996,000
Later cash rounded aud september 30
900,000
August 26 convertible face aud
1,055,800
Vitable equity headline aud
2,500,000
Warning
Dates cannot be added into a current net-debt figure. Old secured debt partly converted to notes; subtracting both old principal and new notes would double count. No automatic exercise proceeds or contingent consideration zero assumed.
bear · conditional only
Revenue
14,400,000
Gross margin
0.4
Cash operating cost after rent
6,500,000
Metric
-740,000
Metric label
CIN hypothetical after-rent EBITDA, existing Australian business only
Revenue/margins/cash-costs/multiples are CIN judgment stress inputs, not facts, street forecasts or promised 2027 performance.
No per-share valuation or upside is computed from the three EV sensitivities.
What the diagnostic cannot establish
Latest capital, note conversion formula and acquisition dilution not reconciled.
Legacy June net-income conflict remains held; half-year original is not a quarterly conflict resolution.
Risks and downside mechanism
June reviewed report contains material uncertainty related to going concern and AUD 1.547 m net current liabilities.
Actual H 1 and Q 3 cash outflows differ from management underlying measures; receivable collections/timing adjustments are not sustainable cash margin proof.
12% convertible coupon and remaining secured facility repayments by March 2027 may absorb modest operating gains.
Vitable all-scrip headline AUD 2.5 m over five tranches plus Platform Kicker does not yet yield a fully diluted share denominator.
Elixinol binding agreement to acquire Vitable · Published 2026-09-24 · Covered period event / not specified Terms also summarized in original Oct 14 quarterly corporate update official announcement identity read; full terms not captured; subsequent 429 stopped no retry
Original dates are retained. Bounded source checks are not a complete corporate-actions feed. Author holdings, issuer compensation, relationships and trading conflicts have not been supplied; no absence-of-conflict claim is made.
No current recommendation, target or upside is issued here.
Evidence confidence: high historical original financial statements and issuer capability; limited currentFY 2026 financial/capital evidence Underwriting status: Not Rated; current original-source/capital gate
Business and cannabis exposure: Issuer website explicitly supports medicinal cannabis processing/formulation and controlled S8/S9 supply within broader CDMO services; not a pure cannabis producer.
Security: ASX IDT ordinary shares, pharmaceutical CDMO; distinct from US NYSE IDT Corporation
Capital and unit basis: FY2026 original full accounts and Sep 2/Oct 5 capital notices unreviewed; current unit/fully diluted shares not certified.
Saved quote observation: AUD 0.038 dated 2026-10-23T00:15:00.000Z. This retained observation is not independently certified as a current exchange close, and no target return is computed from it.
CIN’s investment read
Manufacturing utilization can create operating leverage, but revenue that includes disbursements, bad debts or customer financing is not the same as recurring high-margin CDMO cash earnings. Original accessible accounts show a capital-intensive business with substantial secured borrowing; its later FY 2026 turnaround needs the actual filing and a current financing/share bridge.
Why the rating and target are withheld
KnownFY 2026 originals and later capital notices are not yet reconciled, and the historical secured-claim/cash-return bridge is material. Capability plus a saved quote is insufficient for a target.
Original reported figures and dated disclosures
Units, reporting periods and publication dates stay separate. Company statements and CIN assumptions are identified by line; historical facts are not current cash or current ownership.
Conditional capital, funding and valuation work · not price targets
Sensitivity, not an issued opinion. Forecasts, cost assumptions, multiples, discount rates, financing allowances and trial outcomes below are CIN analytical inputs. No probability of clinical success, funded share value or current target is implied by a cash-runway or break-even calculation.
Conditional gross-margin/cost break-even sensitivity only; no complete current enterprise or equity valuation
Inputs and their limits
Scale unit fixed cash cost aud
1,000,000
Why conditional
Scale-free operating break-even sensitivity per AUD 1 m fixed cash operating cost. The actual current cost base is not assumed because the FY2026 original/capital bridge remains unreviewed. No obsolete debt/cash/shares become a target.
Capital and claim bridge
Fy 2025 borrowings carrying aud
10,405,000
Fy 2025 cash aud
503,000
Fy 2025 term deposits aud
3,603,000
Deposit restriction
Loan security mentions term deposit; unrestricted availability not established. Do not automatically subtract all deposits from debt.
Fy 2025 common shares
429,677,870
Fy 2025 employee options schedule only
5,017,320
Separate director options
FY2025 report contains 12 m director options at 10/15/20 c expiringAug 7,2026; expiry/exercise/cessation not assumed current without original 2026 notices.
CIN scale-free sensitivity per AUD 1 m fixed cash operating cost; not actual FY 2026/FY 2027 costs, an earnings forecast or a per-share target. Interest, capex and working capital remain additional funding demands.
CIN scale-free sensitivity per AUD 1 m fixed cash operating cost; not actual FY 2026/FY 2027 costs, an earnings forecast or a per-share target. Interest, capex and working capital remain additional funding demands.
CIN scale-free sensitivity per AUD 1 m fixed cash operating cost; not actual FY 2026/FY 2027 costs, an earnings forecast or a per-share target. Interest, capex and working capital remain additional funding demands.
CIN assumptions
The three gross margins are CIN sensitivity inputs. AUD 1 m is a scaling unit, not an estimate of actual operating costs.
Break-even sales scale proportionally with actual fixed cash costs and exclude interest, tax, capex and working capital; they are not equity return estimates.
What the diagnostic cannot establish
No full latest original financial/capital report retrieved under permitted route.
No current target/share denominator or qualified upside.
Risks and downside mechanism
Full FY 2026 accounts and post June securities events not reconciled; olderFY 2025 balances cannot be labelled current.
Secured property/receivables and term deposits limit net-cash assumptions; compare gross contractual claims with carrying amounts/fees.
Customer concentration and 1.226 mFY 2025 bad debts challenge revenue quality.
CDMO capacity additions require cash before profitable utilization; company service capability is not a committed order.
Internal FY 2025 summary tables differ from full statements: abbreviated Note 28 omits 9.589 m noncurrent borrowing and directors text mentions a cash-outflow figure inconsistent with printed cashflow statement. Use source-qualified full statements, not an apparent netfinancial position.
Next evidence and thesis tests
Obtain the original FY 2026 full report through a permitted issuer-hosted route or existing authorized copy.
Reconcile Sep 2/Oct 5 securities notices and current debt drawings/pledged deposits.
Test production revenue, cash collection and gross-margin realization separately from disbursements and grants.
Latest original report shows further unreconciled financial inconsistencies or funding terms negate operating leverage.
Customer receivables fail to convert or capacity stays underutilized.
A current share/convertible/secured-claim bridge cannot be tied to primary records.
Original sources and access limits
IDT Australia audited FY 2025 annual report · Published 2025-08-20 · Covered period 2025-06-30 PDF 56 pages; printed 18-21 statements; Notes 14/19/22/23/28 official public document read
IDT issuer-hosted annual reports index · Published not verified · Covered period event / not specified Bounded current page listsFY 2025 newest independently hosted annual; not a claimFY 2026 absent official issuer website read
Original dates are retained. Bounded source checks are not a complete corporate-actions feed. Author holdings, issuer compensation, relationships and trading conflicts have not been supplied; no absence-of-conflict claim is made.
No current recommendation, target or upside is issued here.
Evidence confidence: high for successfully read original Q 2 tables/official updates; full localQ 2 capture refused 403 and not retried Underwriting status: Not Rated; launch financing and current capital gate
Business and cannabis exposure: Operating alcohol-test instruments/training plus developmental delta 9 THC oral-fluid device; no operating cannabis production revenue claimed.
Capital and unit basis: Aug 1 common count known; no current complete options/warrants/debt/launch-financing bridge verified.
Saved quote observation: USD 3.5 dated 2026-10-23T13:30:00.000Z. This retained observation is not independently certified as a current exchange close, and no target return is computed from it.
CIN’s investment read
The core instrument business is improving, but shareholders are also funding an unproven drug-testing launch. The equity debate is the cash economics of that launch and its financing, rather than a cannabis-sector sales multiple. Count no Spin Detect revenue until validated launch, regulatory use and customer adoption are documented.
Why the rating and target are withheld
Operating evidence is improving, but financing through commercialization and a current gross-claim/award denominator are not sufficiently reconciled to issue a 12 month share target.
Original reported figures and dated disclosures
Units, reporting periods and publication dates stay separate. Company statements and CIN assumptions are identified by line; historical facts are not current cash or current ownership.
Evidence item
Reported value & unit
Period / basis
Original reference
Q 2 total revenue
2,444,957 USD
2026-06-30quarterly · US GAAP unaudited · reported fact
Conditional capital, funding and valuation work · not price targets
Sensitivity, not an issued opinion. Forecasts, cost assumptions, multiples, discount rates, financing allowances and trial outcomes below are CIN analytical inputs. No probability of clinical success, funded share value or current target is implied by a cash-runway or break-even calculation.
Core-operating enterprise sensitivity with zero drug-device optionality until source-supported; no per-share target
Inputs and their limits
Launch revenue
0
Launch option value
0
Method rationale
EBITDA sensitivity tests core profitability and R&D normalization; it cannot capitalize an unproven launch while omitting its funding.
Capital and claim bridge
June 30 debt carrying netfees usd
2,284,658
June 30 cash usd
908,208
Aug 1 common shares
2,752,616
Known warrant grants shares
68,750
Known warrant exercise usd
4.5
Warrant basis
62,500 onDec 31,2024 plus 6,250 onMar 1,2025 as described inQ2 filing; current exercise/cancellation status not newly proven.
Options
OriginalMarch 2026 filing mentioned 15,000 options; later expiry/exercise status not certified here; not assumedzero.
Leases preferred nci
Not separately established from bounded current capital evidence; do not invent zero or capitalize rent twice.
bear · conditional only
Revenue
9,500,000
Gross margin
0.43
Cash rd sustaining
1,800,000
Cash sales general admin
2,700,000
Metric
-415,000
Metric label
CIN hypothetical after-rent EBITDA before interest; no device launch revenue
Lifeloc staged Spin Detect development/rollout update · Published 2026-06-15 · Covered period event / not specified Original development/validation/regulatory sequence; not commercial approval official public document read
Lifeloc official SEC entity filing index · Published not verified · Covered period event / not specified Latest non-insider report shown in bounded check Sept 29; does not certify all corporate actions official public document read
Original dates are retained. Bounded source checks are not a complete corporate-actions feed. Author holdings, issuer compensation, relationships and trading conflicts have not been supplied; no absence-of-conflict claim is made.
No current recommendation, target or upside is issued here.
Evidence confidence: High for historical SEC statements and the issuer disclosure index; current underwriting limited because the 2026 report is unavailable. Underwriting status: Not Rated; current original OTC capital and financial evidence gate.
Business and cannabis exposure: Original SEC business describes armed transport, currency processing and compliance services for lawful cannabis. Current issuer website continues to describe commercial operations.
Security: Historical BLPG common stock, with a 2021 one-for-100 reverse split. Exact current OTC tier, unit and capital are not certified.
Capital and unit basis: Current OTC report unavailable; the old 8.25 m common count is not a current fully diluted denominator.
Saved quote observation: USD 0.0372 dated 2026-10-22T20:00:00.000Z. This retained observation is not independently certified as a current exchange close, and no target return is computed from it.
CIN’s investment read
A service provider can monetize cannabis cash logistics without taking cultivation-price risk, but minority common holders sit behind conversion and preference claims. The decision hinge is recurring service cash after those claims, not the value of client currency transported or processed. Current original OTC accounts are needed before that economics can be priced.
Why the rating and target are withheld
The actual June 2026 OTC report is temporarily unavailable, and current convertible, preferred and fully diluted capital cannot be substituted with old basic shares.
Original reported figures and dated disclosures
Units, reporting periods and publication dates stay separate. Company statements and CIN assumptions are identified by line; historical facts are not current cash or current ownership.
Evidence item
Reported value & unit
Period / basis
Original reference
Historicalquarter revenue
1,038,795 USD
2025-03-31quarterly · US GAAP unaudited historical · reported fact
Conditional capital, funding and valuation work · not price targets
Sensitivity, not an issued opinion. Forecasts, cost assumptions, multiples, discount rates, financing allowances and trial outcomes below are CIN analytical inputs. No probability of clinical success, funded share value or current target is implied by a cash-runway or break-even calculation.
Enterprise-only service cash sensitivity; no current equity target
Inputs and their limits
Basis
After-rent operating profitability scale. Client cash is not capitalized, and total liabilities are not substituted for debt.
Unknown current 2026 operating results
Yes
Capital and claim bridge
Historical only 2025 03 31
Notes carrying
474,485
Convertible carrying
363,500
Embedded derivative
435,296
Cash
407,958
Preferred shares
200,000
Common shares
8,250,144
Operating leases
420,580
Finance lease
6,817
Warning
Do not subtract the accounting embedded derivative and also assume maximal conversion of the same notes without one reconciled claim bridge. After-rent operating values already include rent. Historical preferred conversion and reserved-share disclosures contain pre 2021 split figures and require current certificate reconciliation.
bear · conditional only
Metric
150,000
Metric label
CIN illustrative normalized after-rent service EBITDA
Multiple
4
Enterprise value
600,000
Currency
USD
Qualification
Conditional operating sensitivity only, not current earnings, enterprise fair value or a share target. Based on broad historical operating scale; current 2026 accounts remain unverified.
Calculation
metric*multiple
base · conditional only
Metric
250,000
Metric label
CIN illustrative normalized after-rent service EBITDA
Multiple
5
Enterprise value
1,250,000
Currency
USD
Qualification
Conditional operating sensitivity only, not current earnings, enterprise fair value or a share target. Based on broad historical operating scale; current 2026 accounts remain unverified.
Calculation
metric*multiple
bull · conditional only
Metric
400,000
Metric label
CIN illustrative normalized after-rent service EBITDA
Multiple
6
Enterprise value
2,400,000
Currency
USD
Qualification
Conditional operating sensitivity only, not current earnings, enterprise fair value or a share target. Based on broad historical operating scale; current 2026 accounts remain unverified.
Calculation
metric*multiple
CIN assumptions
AUD is not used: these sensitivities are USD. EBITDA of 150/250/400 k and 4/5/6 x are CIN conditional tests, not reported current results or 2027 guidance.
No old common-share denominator or stored quote turns the EV cases into targets.
What the diagnostic cannot establish
Current 2026 original financial accounts, capital terms and security actions remain unverified.
No current return, issued rating or price target.
Risks and downside mechanism
June 2026 cash, earnings, customer concentration, shares and convertible terms are not reconciled.
Historical variable conversion, preferred anti-dilution and purchase-preference claims can materially change ordinary-share value.
Historical diluted EPS units of 20.87 m versus 8.25 m basic are accounting measures, not a current all-claim conversion schedule.
Cash handled for clients is not company cash, revenue or enterprise value.
Thin OTC liquidity, customer concentration, cannabis banking conditions and service compliance costs.
Next evidence and thesis tests
Accessible current issuer or OTC accounts with convertible and preferred terms and an issued-capital schedule.
Actual service cash conversion and customer economics after operating costs.
Source evidence of debt or convertible amendment, resolution or redemption and the current tradable unit.
Latest primary accounts do not reconcile by period, scale or claim attribution.
Contract losses, cost inflation or customer concentration erode recurring cash.
Capital terms consume or dilute the value created by the service enterprise.
Blue Line originalSEC 2024 annual report · Published 2025-03-31 · Covered period 2024-12-31 Business and financial statements; originalnotcurrent official web text success
Issuer-linkedOTC 2026 quarterly report endpoint unavailable · Published 2026-08-06 · Covered period 2026-06-30 Link onoriginalissuerIRpage; no currentfigures extracted UNAVAILABLE:tooltimeout thenoneboundedraw 200 maintenanceHTML notPDF no retry
Original dates are retained. Bounded source checks are not a complete corporate-actions feed. Author holdings, issuer compensation, relationships and trading conflicts have not been supplied; no absence-of-conflict claim is made.
No current recommendation, target or upside is issued here.
Evidence confidence: Primary original financial statements and dated issuer disclosures for specified claims; complete current capital/clinical underwriting remains incomplete Underwriting status: Preliminary initiation underwrite — no supported current equity rating or target
Business and cannabis exposure: Legacy nimacimab targets CB1 receptor biology; CBeyond terminated and development paused. Proposed Redx/Fibrx group is fibrosis-focused, not cannabis sales or an active cannabis-drug revenue business.
Security: Common stock, USD 0.001 par
Transaction status: Proposed Redx transaction announcedAugust 14; closing not verified in this bounded review.
Current share basis: Q2 counts are before the subsequently approved 1-for-8 reverse split. Exact implementation/current diluted bridge not verified; do not divide a current quote into old shares.
Saved quote observation: USD 1.54 dated 2026-10-23T20:00:00.000Z. This retained observation is not independently certified as a current exchange close, and no target return is computed from it.
CIN’s investment read
The decision hinge is transaction economics, not a continuing standalone nimacimab growth story. The Q2 filing records the CBeyond termination, paused R&D and cost cuts.
Potential retained value consists of an adjusted minority interest in a fibrosis developer and a contingent nimacimab monetization right. Neither announced financing gross proceeds nor a CVR is distributable cash for today’s common share.
CIN does not infer a market mispricing from the stored quotation because old shares, the reverse split, new financing, net-cash adjustment and CVR economics are not yet one current basis.
Why the rating and target are withheld
Current split-adjusted diluted capitalization, closing net cash, Redx programme-level risk-adjusted value, financing allocations and CVR net economics are not reconciled. A clinical probability or combined-company valuation would be arbitrary; no current target is issued.
Original reported figures and dated disclosures
Units, reporting periods and publication dates stay separate. Company statements and CIN assumptions are identified by line; historical facts are not current cash or current ownership.
Conditional capital, funding and valuation work · not price targets
Sensitivity, not an issued opinion. Forecasts, cost assumptions, multiples, discount rates, financing allowances and trial outcomes below are CIN analytical inputs. No probability of clinical success, funded share value or current target is implied by a cash-runway or break-even calculation.
Historical funding stress only; a programme-level rNPV is withheld
Inputs and their limits
Liquid resources
10,064,141
Cash use
15,679,591
Cash use period months
6
Capital and claim bridge
Start with separately disclosed cash and investments; restricted cash is excluded where identified.
Apply trailing operating cash use with CIN bear/base/bull multipliers 1.5/1/0.75. These multipliers are sensitivities, not clinical probabilities or management guidance.
No equity-value or per-share conclusion follows from a runway calculation. Financing, trial changes, working capital and commitments can make future cash use materially different.
Conditional transaction bridge
Formula
(current fully diluted combined equity value × actual old-holder ownership + CVR net value allocated to old holders) / split-consistent old-holder equivalent units
Announced old holder percent
5.38
Equity line note
August 21 agreement provides up-toUSD22 m contingent ELOC reduced by funded proceeds overUSD103 m and zero if funded proceeds reachUSD125 m; do not add it automatically to fully funded PIPE.
bear · conditional only
Classification
CIN funding stress diagnostic, not an equity value or price target
Burn multiplier
1.5
Annual cash use
47,038,773
Starting liquid resources
10,064,141
Diagnostic months to zero
2.5674
Cash after 12 months before financing
-36,974,632
Minimum external cash to avoid negative balance at month 12
36,974,632
Currency
USD
Formula
period cash use / period months ×12 × multiplier; starting resources minus annual cash use
base · conditional only
Classification
CIN funding stress diagnostic, not an equity value or price target
Burn multiplier
1
Annual cash use
31,359,182
Starting liquid resources
10,064,141
Diagnostic months to zero
3.8512
Cash after 12 months before financing
-21,295,041
Minimum external cash to avoid negative balance at month 12
21,295,041
Currency
USD
Formula
period cash use / period months ×12 × multiplier; starting resources minus annual cash use
bull · conditional only
Classification
CIN funding stress diagnostic, not an equity value or price target
Burn multiplier
0.75
Annual cash use
23,519,386.5
Starting liquid resources
10,064,141
Diagnostic months to zero
5.1349
Cash after 12 months before financing
-13,455,245.5
Minimum external cash to avoid negative balance at month 12
13,455,245.5
Currency
USD
Formula
period cash use / period months ×12 × multiplier; starting resources minus annual cash use
CIN assumptions
No financing proceeds, asset sales, interest income or future commercial revenue credited.
No recovery value assigned to intellectual property; this is not an assertion that IP is worthless.
What the diagnostic cannot establish
Historical balance-date diagnostic, not current cash or a liquidation estimate.
Cash burn is not stationary in a clinical pipeline; actual programme budgets and trial-stage costs are required.
No funded fully diluted 12-month equity bridge or source-supported success-probability/revenue/cost model; no rating/target/upside.
Risks and downside mechanism
Merger failure, Nasdaq compliance, closing net-cash adjustments, transaction costs and litigation can change old-holder economics materially.
The reported legal accrual is an estimate; the Q2 filing scheduled a retrial for October 2026, but its current outcome has not been verified.
Any Redx clinical asset retains development, regulatory, manufacturing and commercial risk; IND/Fast Track are not marketing approval.
CVR net proceeds may be zero, delayed or reduced by contractual costs; no nimacimab buyer or value is established.
Next evidence and thesis tests
Reconcile executed reverse-split notice, final merger proxy, current basic/nonvoting/prefunded/options/warrants and closing net cash on one basis.
Verify litigation disposition and contingent-liability insurance / transaction adjustment.
Underwrite RXC008 development budget, rights, timelines and a defensible phase-specific clinical and commercial model before a 12 month equity valuation.
Definitive transaction termination or unfavorable net-cash adjustment invalidates the stated pro-forma path.
A monetization agreement without net proceeds to CVR holders does not support a positive CVR value.
Original sources and access limits
Skye Bioscience Q2 2026 Form 10-Q · Published 2026-08-14 · Covered period 2026-06-30 Cover; pp 6/9/14–19; MD&A Recent Developments/Going Concern; Note 11 Full original HTML read via web tool
Skye and Redx transaction and financing announcement · Published 2026-08-14 · Covered period Transaction announcement Transaction Highlights; Pro-forma Ownership; CVRs; Nimacimab and CBeyond Full original HTML read via web tool
Original dates are retained. Bounded source checks are not a complete corporate-actions feed. Author holdings, issuer compensation, relationships and trading conflicts have not been supplied; no absence-of-conflict claim is made.
No current recommendation, target or upside is issued here.
Evidence confidence: Primary original financial statements and dated issuer disclosures for specified claims; complete current capital/clinical underwriting remains incomplete Underwriting status: Preliminary initiation underwrite — no supported current equity rating or target
Business and cannabis exposure: BayMedica cannabinoid commercial operations were wound down and reported as discontinued operations; legacy drug candidates are proposed CVR assets. Proposed Mentari focus is migraine/PACAP therapeutics, not cannabis operating revenue.
Security: Common shares, no par value
Transaction status: Mentari reverse merger proposed; September 29 registration amendment identified. Closing not verified.
Current share basis: Financial statements retrospectively reflectNovember 14,2024 1-for-20 split. Current merger exchange ratio / preferred / warrants / later issuance bridge remains incomplete.
Saved quote observation: USD 1.44 dated 2026-10-23T20:00:00.000Z. This retained observation is not independently certified as a current exchange close, and no target return is computed from it.
CIN’s investment read
The investable question is a small, conditional stake in a financed migraine business plus potential legacy-asset proceeds; old cannabinoid sales are discontinued and cannot support a continuing-sales multiple.
The original filing corrects the stored card’s thousand-fold scaling error. True BayMedica sales fell about 35.7% year on year, while total annual cash use wasUSD8.64 m.
CIN withholds a price target until final ownership, closing net cash and preferred/option/warrant economics are reconciled. The latest ownership clause is 0.97% conditional on minusUSD4.4 m net cash, not an unconditional 1.51% carried from the earlier 10-K.
Why the rating and target are withheld
No reconciled final merger ownership/current diluted capitalization or defensible Mentari clinical/commercial rNPV and CVR valuation. Standalone liquidity is thin and the old commercial business is discontinued; multiplying erroneous legacy revenue would be misleading.
Original reported figures and dated disclosures
Units, reporting periods and publication dates stay separate. Company statements and CIN assumptions are identified by line; historical facts are not current cash or current ownership.
Evidence item
Reported value & unit
Period / basis
Original reference
Cash and equivalents, balance-sheet line excluding separately classified discontinued assets
Expected aggregate Mentari pre-closing financing, grossIncludesUSD50 m previously received convertible notes and accrued interest; not USD 490 m fresh cash payable to old InMed holders.
Conditional capital, funding and valuation work · not price targets
Sensitivity, not an issued opinion. Forecasts, cost assumptions, multiples, discount rates, financing allowances and trial outcomes below are CIN analytical inputs. No probability of clinical success, funded share value or current target is implied by a cash-runway or break-even calculation.
Historical funding stress only; a programme-level rNPV is withheld
Inputs and their limits
Liquid resources
2,234,083
Cash use
8,643,513
Cash use period months
12
Capital and claim bridge
Start with separately disclosed cash and investments; restricted cash is excluded where identified.
Apply trailing operating cash use with CIN bear/base/bull multipliers 1.5/1/0.75. These multipliers are sensitivities, not clinical probabilities or management guidance.
No equity-value or per-share conclusion follows from a runway calculation. Financing, trial changes, working capital and commitments can make future cash use materially different.
Conditional transaction bridge
Formula
Combined equity value × final old-holder ownership plus net legacy distribution/CVR, divided by fully reconciled split-consistent old-holder units
Conditional old holder percent
0.97
Net cash assumption
-4,400,000
Limitations
Latest indexed clause is conditional and full latestS-4 was inaccessible; this is not a completed transaction valuation.
No arbitrary clinical probability is assigned to Mentari or legacy programmes.
bear · conditional only
Classification
CIN funding stress diagnostic, not an equity value or price target
Burn multiplier
1.5
Annual cash use
12,965,269.5
Starting liquid resources
2,234,083
Diagnostic months to zero
2.0678
Cash after 12 months before financing
-10,731,186.5
Minimum external cash to avoid negative balance at month 12
10,731,186.5
Currency
USD
Formula
period cash use / period months ×12 × multiplier; starting resources minus annual cash use
base · conditional only
Classification
CIN funding stress diagnostic, not an equity value or price target
Burn multiplier
1
Annual cash use
8,643,513
Starting liquid resources
2,234,083
Diagnostic months to zero
3.1016
Cash after 12 months before financing
-6,409,430
Minimum external cash to avoid negative balance at month 12
6,409,430
Currency
USD
Formula
period cash use / period months ×12 × multiplier; starting resources minus annual cash use
bull · conditional only
Classification
CIN funding stress diagnostic, not an equity value or price target
Burn multiplier
0.75
Annual cash use
6,482,634.75
Starting liquid resources
2,234,083
Diagnostic months to zero
4.1355
Cash after 12 months before financing
-4,248,551.75
Minimum external cash to avoid negative balance at month 12
4,248,551.75
Currency
USD
Formula
period cash use / period months ×12 × multiplier; starting resources minus annual cash use
CIN assumptions
No financing proceeds, asset sales, interest income or future commercial revenue credited.
No recovery value assigned to intellectual property; this is not an assertion that IP is worthless.
What the diagnostic cannot establish
Historical balance-date diagnostic, not current cash or a liquidation estimate.
Cash burn is not stationary in a clinical pipeline; actual programme budgets and trial-stage costs are required.
No funded fully diluted 12-month equity bridge or source-supported success-probability/revenue/cost model; no rating/target/upside.
Risks and downside mechanism
Nasdaq minimum-equity deficiency, a near-term funding gap and merger execution dominate the standalone case. Expected financing belongs to the conditional combined group.
Legacy asset sales/licenses and CVR proceeds are not assured; a pre-IND meeting is not FDA clearance or clinical efficacy.
Mentari pipeline valuation, rights, trial costs and commercial assumptions have not been independently underwritten in this bounded four-company pass.
The latest S-4 full HTML could not be read through the tool; only the specific official indexed ownership clause was verified. Current meeting/split terms are not asserted from secondary summaries.
Next evidence and thesis tests
Fully inspect final effective S-4 / definitive proxy and reconcile final exchange ratio, closing net cash, new preferred/pre-funded instruments and transaction costs.
Verify Nasdaq plan and current cash/financing actually received.
Build separate Mentari pipeline rNPV and legacy-CVR net-proceeds model without counting gross financing as old-holder equity.
Merger financing or listing conditions fail.
Final old-holder ownership or net cash is materially worse than the conditional illustration.
Original sources and access limits
InMed FY2026 Form 10-K · Published 2026-09-09 · Covered period 2026-06-30 Cover; F4–F7; Note 3 Discontinued Operations; Notes 6–8,12–13; Liquidity Full original HTML read via web tool
InMed FY2026 results and corporate update · Published 2026-09-09 · Covered period 2026-06-30 Proposed Merger / CVR / Discontinued Operations / financial tables Full original HTML read via web tool
InMed amended merger registration statement, Amendment 2 · Published 2026-09-29 · Covered period Proposed transaction Reasons for Merger pp 154–155; ownership conditional on minusUSD4.4 m InMed net cash Official SEC search-index text verified for cited ownership clause; full HTML open failed internally; no claim of full document review
Original dates are retained. Bounded source checks are not a complete corporate-actions feed. Author holdings, issuer compensation, relationships and trading conflicts have not been supplied; no absence-of-conflict claim is made.
No current recommendation, target or upside is issued here.
Evidence confidence: Primary original financial statements and dated issuer disclosures for specified claims; complete current capital/clinical underwriting remains incomplete Underwriting status: Preliminary initiation underwrite — no supported current equity rating or target
Business and cannabis exposure: CRB-913 is a CB1 inverse-agonist obesity programme. CRB-701 oncology ADC is a separate non-cannabis asset; do not label the whole group cannabis sales.
Security: Common stock, USD 0.0001 par
Current share basis: June common/pre-funded/options/RSU counts and July-to-filing ATM known; later ATM/grants and exact October fully diluted share bridge not fully reconciled.
Saved quote observation: USD 4.05 dated 2026-10-23T20:00:00.000Z. This retained observation is not independently certified as a current exchange close, and no target return is computed from it.
CIN’s investment read
The genuine decision hinge is whether the differentiated CB1 programme can sustain efficacy and psychiatric tolerability at longer duration while the oncology programme advances without financing eroding old-holder returns.
CANYON-1 is a useful early signal: the issuer reports 254 randomized adults and 5.0% placebo-adjusted weight reduction at 60 mg at week 12. It is not a late-stage approval probability or a head-to-head advantage over GLP-1 therapy.
Cash alone understates reported liquidity because investments addUSD94.571 m; conversely, gross liquidity is not surplus equity because six-month operating cash use wasUSD55.197 m and the clinical pipeline carries commitments.
Why the rating and target are withheld
No defensible programme-level clinical success probabilities, net licensed cash-flow forecasts, development-cost schedule and October fully diluted financing bridge. Reported liquidity supports a funding diagnostic, not a price target or a positive clinical investment conclusion.
Original reported figures and dated disclosures
Units, reporting periods and publication dates stay separate. Company statements and CIN assumptions are identified by line; historical facts are not current cash or current ownership.
Conditional capital, funding and valuation work · not price targets
Sensitivity, not an issued opinion. Forecasts, cost assumptions, multiples, discount rates, financing allowances and trial outcomes below are CIN analytical inputs. No probability of clinical success, funded share value or current target is implied by a cash-runway or break-even calculation.
Historical funding stress only; a programme-level rNPV is withheld
Inputs and their limits
Liquid resources
117,941,000
Cash use
55,197,000
Cash use period months
6
Capital and claim bridge
Start with separately disclosed cash and investments; restricted cash is excluded where identified.
Apply trailing operating cash use with CIN bear/base/bull multipliers 1.5/1/0.75. These multipliers are sensitivities, not clinical probabilities or management guidance.
No equity-value or per-share conclusion follows from a runway calculation. Financing, trial changes, working capital and commitments can make future cash use materially different.
bear · conditional only
Classification
CIN funding stress diagnostic, not an equity value or price target
Burn multiplier
1.5
Annual cash use
165,591,000
Starting liquid resources
117,941,000
Diagnostic months to zero
8.5469
Cash after 12 months before financing
-47,650,000
Minimum external cash to avoid negative balance at month 12
47,650,000
Currency
USD
Formula
period cash use / period months ×12 × multiplier; starting resources minus annual cash use
base · conditional only
Classification
CIN funding stress diagnostic, not an equity value or price target
Burn multiplier
1
Annual cash use
110,394,000
Starting liquid resources
117,941,000
Diagnostic months to zero
12.8204
Cash after 12 months before financing
7,547,000
Minimum external cash to avoid negative balance at month 12
0
Currency
USD
Formula
period cash use / period months ×12 × multiplier; starting resources minus annual cash use
bull · conditional only
Classification
CIN funding stress diagnostic, not an equity value or price target
Burn multiplier
0.75
Annual cash use
82,795,500
Starting liquid resources
117,941,000
Diagnostic months to zero
17.0938
Cash after 12 months before financing
35,145,500
Minimum external cash to avoid negative balance at month 12
0
Currency
USD
Formula
period cash use / period months ×12 × multiplier; starting resources minus annual cash use
CIN assumptions
No financing proceeds, asset sales, interest income or future commercial revenue credited.
No recovery value assigned to intellectual property; this is not an assertion that IP is worthless.
What the diagnostic cannot establish
Historical balance-date diagnostic, not current cash or a liquidation estimate.
Cash burn is not stationary in a clinical pipeline; actual programme budgets and trial-stage costs are required.
No funded fully diluted 12-month equity bridge or source-supported success-probability/revenue/cost model; no rating/target/upside.
Risks and downside mechanism
Longer exposure can alter psychiatric/safety findings, weight-loss durability and adherence. Cross-trial comparisons cannot establish superiority.
CRB-701 licensed economics include potential development/regulatory and commercial milestones and low-double-digit royalties; rNPV must deduct these and programme costs.
Trial expansion, cash burn, ATM sales, inducement grants and nominal-price pre-funded warrants can change per-share returns.
The original current financials largely tie to the stored snapshot; old conflict flags remain unresolved but do not prove a defect in the current cash orQ2 net-loss figure.
Next evidence and thesis tests
Review complete CANYON-1 efficacy/safety detail and longer-duration plan; do not import cross-trial claims as comparative proof.
Reconcile July-to-current ATM activity, all pre-funded/option/RSU dilution and current net liquidity.
Model CRB-913 and CRB-701 separately, including development costs, licence milestones/royalties, financing and probability evidence before rNPV.
Dose-limiting psychiatric effects or loss of efficacy separation in longer controlled trials.
Funding/cap-table dilution makes milestone success unattractive per current share.
Original sources and access limits
Corbus Q2 2026 Form 10-Q · Published 2026-08-06 · Covered period 2026-06-30 Cover; pp 3/7–9; Notes 9,11–16; MD&A Liquidity Full original HTML read via web tool
Corbus CANYON-1 topline disclosure · Published 2026-09-14 · Covered period 12-week treatment, four-week follow-up Study Design; Efficacy; Safety caveat; Next Steps Full original HTML read via web tool
Corbus TEMPO-1 first-patient announcement · Published 2026-09-29 · Covered period Trial initiation First patient dosed; study purpose Full original HTML read via web tool
Original dates are retained. Bounded source checks are not a complete corporate-actions feed. Author holdings, issuer compensation, relationships and trading conflicts have not been supplied; no absence-of-conflict claim is made.
No current recommendation, target or upside is issued here.
Evidence confidence: Primary original financial statements and dated issuer disclosures for specified claims; complete current capital/clinical underwriting remains incomplete Underwriting status: Preliminary initiation underwrite — no supported current equity rating or target
Business and cannabis exposure: IGC-AD1 is an investigational cannabinoid-based / partial-CB1-agonist Alzheimer agitation programme; wellness/white-label activity is separate. AI platform announcements are not approved-drug revenue.
Security: Common stock, USD 0.0001 par
Current share basis: June/August basic shares verified, but subscribed-not-issued 4.274853 m, options/nonvested awards, convertible terms and later ATM issuance require a current bridge.
Saved quote observation: USD 0.246 dated 2026-10-23T20:19:00.000Z. This retained observation is not independently certified as a current exchange close, and no target return is computed from it.
CIN’s investment read
The hinge is controlled CALMA efficacy and a funded path beyond readout. Completed enrollment reduces recruitment uncertainty but does not establish that IGC-AD1 works or is approved.
The balance sheet has onlyUSD0.331 m reported cash against six-month operating cash use ofUSD2.573 m. The issuer’s twelve-month liquidity belief relies on anticipated financing and conditional borrowing, not cash in hand.
PRISM/MINT-AD may create options, but the October announcement describes intended applications and evaluated commercial channels; no validated contracted earnings stream is available to capitalize.
Why the rating and target are withheld
Missing a fully funded current common-equity/convertible/award bridge and defensible clinical rNPV inputs. Conditional bank capacity is not cash; no arbitrary probability is assigned to pending phase 2 results, and AI announcements are not assumed revenue.
Original reported figures and dated disclosures
Units, reporting periods and publication dates stay separate. Company statements and CIN assumptions are identified by line; historical facts are not current cash or current ownership.
Conditional capital, funding and valuation work · not price targets
Sensitivity, not an issued opinion. Forecasts, cost assumptions, multiples, discount rates, financing allowances and trial outcomes below are CIN analytical inputs. No probability of clinical success, funded share value or current target is implied by a cash-runway or break-even calculation.
Historical funding stress only; a programme-level rNPV is withheld
Inputs and their limits
Liquid resources
354,000
Cash use
2,573,000
Cash use period months
6
Capital and claim bridge
Start with separately disclosed cash and investments; restricted cash is excluded where identified.
Apply trailing operating cash use with CIN bear/base/bull multipliers 1.5/1/0.75. These multipliers are sensitivities, not clinical probabilities or management guidance.
No equity-value or per-share conclusion follows from a runway calculation. Financing, trial changes, working capital and commitments can make future cash use materially different.
bear · conditional only
Classification
CIN funding stress diagnostic, not an equity value or price target
Burn multiplier
1.5
Annual cash use
7,719,000
Starting liquid resources
354,000
Diagnostic months to zero
0.5503
Cash after 12 months before financing
-7,365,000
Minimum external cash to avoid negative balance at month 12
7,365,000
Currency
USD
Formula
period cash use / period months ×12 × multiplier; starting resources minus annual cash use
base · conditional only
Classification
CIN funding stress diagnostic, not an equity value or price target
Burn multiplier
1
Annual cash use
5,146,000
Starting liquid resources
354,000
Diagnostic months to zero
0.8255
Cash after 12 months before financing
-4,792,000
Minimum external cash to avoid negative balance at month 12
4,792,000
Currency
USD
Formula
period cash use / period months ×12 × multiplier; starting resources minus annual cash use
bull · conditional only
Classification
CIN funding stress diagnostic, not an equity value or price target
Burn multiplier
0.75
Annual cash use
3,859,500
Starting liquid resources
354,000
Diagnostic months to zero
1.1007
Cash after 12 months before financing
-3,505,500
Minimum external cash to avoid negative balance at month 12
3,505,500
Currency
USD
Formula
period cash use / period months ×12 × multiplier; starting resources minus annual cash use
CIN assumptions
No financing proceeds, asset sales, interest income or future commercial revenue credited.
No recovery value assigned to intellectual property; this is not an assertion that IP is worthless.
What the diagnostic cannot establish
Historical balance-date diagnostic, not current cash or a liquidation estimate.
Cash burn is not stationary in a clinical pipeline; actual programme budgets and trial-stage costs are required.
No funded fully diluted 12-month equity bridge or source-supported success-probability/revenue/cost model; no rating/target/upside.
Risks and downside mechanism
CALMA remains a placebo-controlled phase 2 programme; safety, effect size, missing data, multiplicity and later trial requirements can change the investment case.
Net carrying debt understates contractual face claims when original issue discounts and derivative conversion features are present.
Current share count omits future subscribed shares and contingent awards; later ATM/convertible dilution is material.
Wellness and white-label sales are small and do not validate pharmaceutical clinical outcomes. The stored financial figures checked here are not blanked solely because a target is unavailable.
Next evidence and thesis tests
Verify CALMA topline dataset, protocol-defined endpoint analysis, safety and regulatory next-stage plan after unblinding.
Reconcile actual current cash, drawn/available bank facility, note face values/conversion terms, later ATM and all subscribed/performance equity.
Build programme development-cost and commercial-rights model with explicit probability evidence and financing before a 12 month target.
No clinically meaningful placebo-adjusted effect or an adverse safety imbalance.
Funding cannot reach the next meaningful milestone without unacceptable per-share dilution.
Original sources and access limits
IGC Pharma Q2 2026 Form 10-Q · Published 2026-08-17 · Covered period 2026-06-30 Cover; pp 4/7/9; Notes 2,11,13–15,17; MD&A Liquidity Full original HTML read via web tool
IGC CALMA phase 2 enrollment completion · Published 2026-09-28 · Covered period Enrollment through release 168 randomized; follow-up/unblinding schedule; trial design Full original HTML read via web tool
IGC PRISM AI platform announcement · Published 2026-10-13 · Covered period Platform announcement PRISM intended applications / evaluated commercial pathways Full original HTML read via web tool
Original dates are retained. Bounded source checks are not a complete corporate-actions feed. Author holdings, issuer compensation, relationships and trading conflicts have not been supplied; no absence-of-conflict claim is made.